NR2F1 and liver cancer: Indeed, GATA3-AS1-driven tumour growth and metastasis in liver cancer are mediated by GATA3 [142], and NR2F1-AS1 was shown to have adverse effects in pancreatic cancer by activating the NR2F1/AKT/MTOR axis [143].